1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 68, 2017
  5. Article

Annual Review of Medicine

Volume 68, 2017

Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models

Abstract

Thoracic aortic diseases, including aneurysms and dissections of the thoracic aorta, are a major cause of morbidity and mortality. Risk factors for thoracic aortic disease include increased hemodynamic forces on the ascending aorta, typically due to poorly controlled hypertension, and heritable genetic variants. The altered genes predisposing to thoracic aortic disease either disrupt smooth muscle cell (SMC) contraction or adherence to an impaired extracellular matrix, or decrease canonical transforming growth factor beta (TGF-β) signaling. Paradoxically, TGF-β hyperactivity has been postulated to be the primary driver for the disease. More recently, it has been proposed that the response of aortic SMCs to the hemodynamic load on a structurally defective aorta is the primary driver of thoracic aortic disease, and that TGF-β overactivity in diseased aortas is a secondary, unproductive response to restore tissue function. The engineering of mouse models of inherited aortopathies has identified potential therapeutic agents to prevent thoracic aortic disease.

Keyword(s): ACTA2, angiotensin receptor, aortopathy, losartan, Marfan syndrome, mutation, phenotype, TGF-β, thoracic aortic disease
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-100415-022956
2017-01-14
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-100415-022956.html?itemId=/content/journals/10.1146/annurev-med-100415-022956&mimeType=html&fmt=ahah

Literature Cited

  1. Hiratzka LF, Bakris GL, Beckman JA. 1.  et al. 2010. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 121:13e266–e369 [Google Scholar]
  2. Howard DP, Banerjee A, Fairhead JF. 2.  et al. 2013. Population-based study of incidence and outcome of acute aortic dissection and premorbid risk factor control: 10-year results from the Oxford Vascular Study. Circulation 127:202031–37 [Google Scholar]
  3. Prakash SK, Haden-Pinneri K, Milewicz DM. 3.  et al. 2011. Susceptibility to acute thoracic aortic dissections in patients dying outside the hospital: an autopsy study. Am. Heart J. 162:3474–79 [Google Scholar]
  4. Coady MA, Rizzo JA, Hammond GL. 4.  et al. 1997. What is the appropriate size criterion for resection of thoracic aortic aneurysms?. J. Thorac. Cardiovasc. Surg. 113:3476–91 [Google Scholar]
  5. Elefteriades JA. 5.  2002. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann. Thorac. Surg. 74:5S1877–S1880 [Google Scholar]
  6. Pape LA, Tsai TT, Isselbacher EM. 6.  et al. 2007. Aortic diameter > or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 116:101120–27 [Google Scholar]
  7. Milewicz DM, Guo D, Tran-Fadulu V. 7.  et al. 2008. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu. Rev. Genom. Hum. Genet. 9:283–302 [Google Scholar]
  8. Humphrey JD, Milewicz DM, Tellides G. 8.  et al. 2014. Cell biology. Dysfunctional mechanosensing in aneurysms. Science 344:6183477–79 [Google Scholar]
  9. Humphrey JD, Schwartz MA, Tellides G. 9.  et al. 2015. Role of mechanotransduction in vascular biology: focus on thoracic aortic aneurysms and dissections. Circ. Res. 116:81448–61 [Google Scholar]
  10. Nienaber CA, Fattori R, Mehta RH. 10.  et al. 2004. Gender-related differences in acute aortic dissection. Circulation 109:243014–21 [Google Scholar]
  11. Lederle FA, Johnson GR, Wilson SE. 11.  et al. 1997. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann. Intern. Med. 126:6441–49 [Google Scholar]
  12. Kang SS, Littooy FN, Gupta SR. 12.  et al. 1999. Higher prevalence of abdominal aortic aneurysms in patients with carotid stenosis but without diabetes. Surgery 126:4687–91 [Google Scholar]
  13. Shantikumar S, Ajjan R, Porter KE. 13.  et al. 2010. Diabetes and the abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 39:2200–7 [Google Scholar]
  14. Prakash SK, Pedroza C, Khalil YA. 14.  et al. 2012. Diabetes and reduced risk for thoracic aortic aneurysms and dissections: a nationwide case-control study. J. Am. Heart Assoc. 1:2piijah3–e000323 [Google Scholar]
  15. Theivacumar NS, Stephenson MA, Mistry H. 15.  et al. 2014. Diabetics are less likely to develop thoracic aortic dissection: a 10-year single-center analysis. Ann. Vasc. Surg. 28:2427–32 [Google Scholar]
  16. He X, Liu X, Liu W. 16.  et al. 2015. Association between diabetes and risk of aortic dissection: a case-control study in a Chinese population. PLOS ONE 10:11e0142697 [Google Scholar]
  17. Davis EC. 17.  1993. Smooth muscle cell to elastic lamina connections in developing mouse aorta. Role in aortic medial organization. Lab. Investig. 68:189–99 [Google Scholar]
  18. Pfaff M, Reinhardt DP, Sakai LY. 18.  et al. 1996. Cell adhesion and integrin binding to recombinant human fibrillin-1. FEBS Lett 384:3247–50 [Google Scholar]
  19. Segura AM, Luna RE, Horiba K. 19.  et al. 1998. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome 2. Circulation 98:Suppl. 19II331–II337 [Google Scholar]
  20. Ikonomidis JS, Jones JA, Barbour JR. 20.  et al. 2007. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J. Thorac. Cardiovasc. Surg. 133:41028–36 [Google Scholar]
  21. McKusick VA. 21.  1995. The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. Circulation 11:321–42 [Google Scholar]
  22. Boileau C, Jondeau G, Babron MC. 22.  et al. 1993. Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. Am. J. Hum. Genet. 53:146–54 [Google Scholar]
  23. Mizuguchi T, Collod-Beroud G, Akiyama T. 23.  et al. 2004. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat. Genet. 36:8855–60 [Google Scholar]
  24. Loeys BL, Chen J, Neptune ER. 24.  et al. 2005. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat. Genet. 37:3275–81 [Google Scholar]
  25. Inamoto S, Kwartler CS, Lafont AL. 25.  et al. 2010. TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. Cardiovasc. Res. 88:3520–29 [Google Scholar]
  26. Boileau C, Guo DC, Hanna N. 26.  et al. 2012. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat. Genet. 44:8916–21 [Google Scholar]
  27. Lindsay ME, Schepers D, Bolar NA. 27.  et al. 2012. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet. 44:8922–27 [Google Scholar]
  28. Nicod P, Bloor C, Godfrey M. 28.  et al. 1989. Familial aortic dissecting aneurysm. J. Am. Coll. Cardiol. 13:4811–19 [Google Scholar]
  29. Tran-Fadulu V, Pannu H, Kim DH. 29.  et al. 2009. Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J. Med. Genet. 46:9607–13 [Google Scholar]
  30. Biddinger A, Rocklin M, Coselli J. 30.  et al. 1997. Familial thoracic aortic dilatations and dissections: a case control study. J. Vasc. Surg. 25:3506–11 [Google Scholar]
  31. Coady MA, Davies RR, Roberts M. 31.  et al. 1999. Familial patterns of thoracic aortic aneurysms. Arch. Surg. 134:4361–67 [Google Scholar]
  32. Milewicz DM, Chen H, Park ES. 32.  et al. 1998. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am. J. Cardiol. 82:4474–79 [Google Scholar]
  33. Milewicz DM, Trybus KM, Sweeney HL. 33.  et al. 2016. Smooth muscle cell contractile function and thoracic aortic aneurysms and dissections. Arterioscler. Thromb. Vasc. Biol. In press
  34. Guo DC, Pannu H, Papke CL. 34.  et al. 2007. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat. Genet. 39:1488–93 [Google Scholar]
  35. Guo DC, Papke CL, Tran-Fadulu V. 35.  et al. 2009. Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am. J. Hum. Genet. 84:5617–27 [Google Scholar]
  36. Milewicz DM, Ostergaard JR, La-Kokko LM. 36.  et al. 2010. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am. J. Med. Genet. A 152A:102437–43 [Google Scholar]
  37. Zhu L, Vranckx R, Khau Van KP. 37.  et al. 2006. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat. Genet. 38:3343–49 [Google Scholar]
  38. Pannu H, Tran-Fadulu V, Papke CL. 38.  et al. 2007. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum. Mol. Genet. 16:203453–62 [Google Scholar]
  39. Wang L, Guo DC, Cao J. 39.  et al. 2010. Mutations in myosin light chain kinase cause familial aortic dissections. Am. J. Hum. Genet. 87:5701–7 [Google Scholar]
  40. Guo DC, Regalado E, Casteel DE. 40.  et al. 2013. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am. J. Hum. Genet. 93:2398–404 [Google Scholar]
  41. Barbier M, Gross MS, Aubart M. 41.  et al. 2014. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am. J. Hum. Genet. 95:6736–43 [Google Scholar]
  42. Guo DC, Regalado ES, Gong L. 42.  et al. 2016. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ. Res. 118:6928–34 [Google Scholar]
  43. Szabo Z, Crepeau MW, Mitchell AL. 43.  et al. 2006. Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene. J. Med. Genet. 43:3255–58 [Google Scholar]
  44. Hucthagowder V, Sausgruber N, Kim KH. 44.  et al. 2006. Fibulin-4: a novel gene for an autosomal recessive cutis laxa syndrome. Am. J. Hum. Genet. 78:61075–80 [Google Scholar]
  45. Kuang SQ, Medina-Martinez O, Guo DC. 45.  et al. 2016. FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. J. Clin. Investig. 126:3948–61 [Google Scholar]
  46. LeMaire SA, McDonald ML, Guo DC. 46.  et al. 2011. Genome-wide association study identifies a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1. Nat. Genet. 43:10996–1000 [Google Scholar]
  47. Kuang SQ, Guo DC, Prakash SK. 47.  et al. 2011. Recurrent chromosome 16p13.1 duplications are a risk factor for aortic dissections. PLOS Genet 7:6e1002118 [Google Scholar]
  48. Prakash SK, LeMaire SA, Guo DC. 48.  et al. 2010. Rare copy number variants disrupt genes regulating vascular smooth muscle cell adhesion and contractility in sporadic thoracic aortic aneurysms and dissections. Am. J. Hum. Genet. 87:6743–56 [Google Scholar]
  49. Hiratzka LF, Bakris GL, Beckman JA. 49.  et al. 2010. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J. Am. Coll. Cardiol. 55:14e27–e129 [Google Scholar]
  50. Krista LM, Waibel PE, Shoffner RN. 50.  et al. 1967. Natural dissecting aneurysm (aortic rupture) and blood pressure in the turkey. Nature 214:50931162–63 [Google Scholar]
  51. Wheat MW Jr, Palmer RF, Bartley TD. 51.  et al. 1965. Treatment of dissecting aneurysms of the aorta without surgery. J. Thorac. Cardiovasc. Surg. 50:364–73 [Google Scholar]
  52. Shores J, Berger KR, Murphy EA. 52.  et al. 1994. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N. Engl. J. Med. 330:191335–41 [Google Scholar]
  53. Jondeau G, Detaint D, Tubach F. 53.  et al. 2012. Aortic event rate in the Marfan population: a cohort study. Circulation 125:2226–32 [Google Scholar]
  54. Murdoch JL, Walker BA, Halpern BL. 54.  et al. 1972. Life expectancy and causes of death in the Marfan syndrome. N. Engl. J. Med. 286:15804–8 [Google Scholar]
  55. Bentall H, De Bono A. 55.  1968. A technique for complete replacement of the ascending aorta. Thorax 23:4338–39 [Google Scholar]
  56. Gott VL, Cameron DE, Alejo DE. 56.  et al. 2002. Aortic root replacement in 271 Marfan patients: a 24-year experience. Ann. Thorac. Surg. 73:2438–43 [Google Scholar]
  57. David TE, David CM, Manlhiot C. 57.  et al. 2015. Outcomes of aortic valve-sparing operations in Marfan syndrome. J. Am. Coll. Cardiol. 66:131445–53 [Google Scholar]
  58. Coselli JS, Volguina IV, LeMaire SA. 58.  et al. 2014. Early and 1-year outcomes of aortic root surgery in patients with Marfan syndrome: a prospective, multicenter, comparative study. J. Thorac. Cardiovasc. Surg. 147:61758–67 [Google Scholar]
  59. Silverman DI, Burton KJ, Gray J. 59.  et al. 1995. Life expectancy in the Marfan syndrome. Am. J. Cardiol. 75:2157–60 [Google Scholar]
  60. Finkbohner R, Johnston D, Crawford ES. 60.  et al. 1995. Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation 91:3728–33 [Google Scholar]
  61. Bunton TE, Biery NJ, Myers L. 61.  et al. 2001. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ. Res. 88:137–43 [Google Scholar]
  62. Habashi JP, Judge DP, Holm TM. 62.  et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:5770117–21 [Google Scholar]
  63. Lavoie P, Robitaille G, Agharazii M. 63.  et al. 2005. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 23:101895–903 [Google Scholar]
  64. Lim DS, Lutucuta S, Bachireddy P. 64.  et al. 2001. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103:6789–91 [Google Scholar]
  65. Robertson IB, Rifkin DB. 65.  2013. Unchaining the beast; insights from structural and evolutionary studies on TGFbeta secretion, sequestration, and activation. Cytokine Growth Factor Rev 24:4355–72 [Google Scholar]
  66. Zilberberg L, Todorovic V, Dabovic B. 66.  et al. 2012. Specificity of latent TGF-beta binding protein (LTBP) incorporation into matrix: role of fibrillins and fibronectin. J. Cell. Physiol. 227:123828–36 [Google Scholar]
  67. Shi M, Zhu J, Wang R. 67.  et al. 2011. Latent TGF-beta structure and activation. Nature 474:7351343–49 [Google Scholar]
  68. Wipff PJ, Rifkin DB, Meister JJ. 68.  et al. 2007. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179:61311–23 [Google Scholar]
  69. Crawford SE, Stellmach V, Murphy-Ullrich JE. 69.  et al. 1998. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:71159–70 [Google Scholar]
  70. Yu Q, Stamenkovic I. 70.  2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes. Dev. 14:2163–76 [Google Scholar]
  71. Gibbons GH, Pratt RE, Dzau VJ. 71.  et al. 1992. Vascular smooth muscle cell hypertrophy versus hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Investig. 90:2456–61 [Google Scholar]
  72. Bellini C, Korneva A, Zilberberg L. 72.  et al. 2016. Differential ascending and descending aortic mechanics parallel aneurysmal propensity in a mouse model of Marfan syndrome. J. Biomech. 49:122383–89 [Google Scholar]
  73. Lee JJ, Galatioto J, Rao S. 73.  et al. 2016. Losartan attenuates degradation of aorta and lung tissue micromechanics in a mouse model of severe Marfan syndrome. Ann. Biomed. Eng. 44:102994–3006 [Google Scholar]
  74. Cook JR, Carta L, Bénard L. 74.  et al. 2014. Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J. Clin. Investig. 124:31329–39 [Google Scholar]
  75. Koibuchi Y, Lee WS, Gibbons GH. 75.  et al. 1993. Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II. Hypertension 21:6 Pt. 21046–50 [Google Scholar]
  76. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V. 76.  et al. 2005. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111:192509–17 [Google Scholar]
  77. Wang Y, It-Oufella H, Herbin O. 77.  et al. 2010. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Investig. 120:2422–32 [Google Scholar]
  78. Cook JR, Clayton NP, Carta L. 78.  et al. 2015. Dimorphic effects of transforming growth factor-beta signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 35:4911–17 [Google Scholar]
  79. Huang J, Yamashiro Y, Papke CL. 79.  et al. 2013. Angiotensin-converting enzyme-induced activation of local angiotensin signaling is required for ascending aortic aneurysms in fibulin-4-deficient mice. Sci. Transl. Med. 5:183183ra58 [Google Scholar]
  80. Moltzer E, Te RL, Swagemakers SM. 80.  et al. 2011. Impaired vascular contractility and aortic wall degeneration in fibulin-4 deficient mice: effect of angiotensin II type 1 (AT1) receptor blockade. PLOS ONE 6:8e23411 [Google Scholar]
  81. Chung AW, Yang HH, Radomski MW. 81.  et al. 2008. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ. Res. 102:8e73–e85 [Google Scholar]
  82. Emrich FC, Okamura H, Dalal AR. 82.  et al. 2015. Enhanced caspase activity contributes to aortic wall remodeling and early aneurysm development in a murine model of Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 35:1146–54 [Google Scholar]
  83. Gao N, Huang J, He W. 83.  et al. 2013. Signaling through myosin light chain kinase in smooth muscles. J. Biol. Chem. 288:117596–605 [Google Scholar]
  84. Lu H, Fagnant PM, Bookwalter CS. 84.  et al. 2015. Vascular disease-causing mutation R258C in ACTA2 disrupts actin dynamics and interaction with myosin. PNAS 112:31E4168–E4177 [Google Scholar]
  85. Sanford LP, Ormsby I, Gittenberger-de Groot AC. 85.  et al. 1997. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124:132659–70 [Google Scholar]
  86. Chen S, Lechleider RJ. 86.  2004. Transforming growth factor-beta-induced differentiation of smooth muscle from a neural crest stem cell line. Circ. Res. 94:91195–202 [Google Scholar]
  87. Chen J, Peters A, Papke C. 87.  et al. 2016. Deficiency of smooth muscle α-actin leads to NF-κB-dependent hypersensitivity to angiotensin II and aortic enlargement. Circ. Res. In press
  88. Hollister DW, Godfrey M, Sakai LY. 88.  et al. 1990. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N. Engl. J. Med. 323:3152–59 [Google Scholar]
  89. Milewicz DM, Pyeritz RE, Crawford ES. 89.  et al. 1992. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J. Clin. Investig. 89:179–86 [Google Scholar]
  90. Matyas G, Alonso S, Patrignani A. 90.  et al. 2007. Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum. Genet. 122:123–32 [Google Scholar]
  91. Yang HH, van Breeman C, Chung AW. 91.  et al. 2010. Vasomotor dysfunction in the thoracic aorta of Marfan syndrome is associated with accumulation of oxidative stress. Vasc. Pharmacol. 52:1–237–45 [Google Scholar]
  92. Papke CL, Cao J, Kwartler CS. 92.  et al. 2013. Smooth muscle hyperplasia due to loss of smooth muscle alpha-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-beta. Hum. Mol. Genet. 22:153123–37 [Google Scholar]
  93. Crosas-Molist E, Meirelles T, Lopez-Luque J. 93.  et al. 2015. Vascular smooth muscle cell phenotypic changes in patients with Marfan syndrome. Arterioscler. Thromb. Vasc. Biol. 35:4960–72 [Google Scholar]
  94. Carta L, Smaldone S, Zilberberg L. 94.  et al. 2009. MAPKp38 is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1) null mice. J. Biol. Chem. 284:95630–36 [Google Scholar]
  95. Doyle JJ, Doyle AJ, Wilson NK. 95.  et al. 2015. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. eLife 4:e08648 [Google Scholar]
  96. Simpson CF, Kling JM, Palmer RF. 96.  et al. 1968. The use of propranolol for the protection of turkeys from the development of beta-aminopropionitrile-induced aortic ruptures. Angiology 19:7414–18 [Google Scholar]
  97. Groenink M, den Hartog AW, Franken R. 97.  et al. 2013. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur. Heart J. 34:453491–500 [Google Scholar]
  98. Franken R, den Hartog AW, Radonic T. 98.  et al. 2015. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ. Cardiovasc. Genet. 8:2383–88 [Google Scholar]
  99. Lacro RV, Dietz HC, Sleeper LA. 99.  et al. 2014. Atenolol versus losartan in children and young adults with Marfan's syndrome. N. Engl. J. Med. 371:222061–71 [Google Scholar]
  100. Milleron O, Arnoult F, Ropers J. 100.  et al. 2015. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. 36:322160–66 [Google Scholar]
  101. Forteza A, Evangelista A, Sanchez V. 101.  et al. 2016. Efficacy of losartan versus atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur. Heart J. 37:12978–85 [Google Scholar]
  102. Simpson CF, Taylor WJ. 102.  1982. Effect of hydralazine on aortic rupture induced by B-aminopropionitrile in turkeys. Circulation 65:4704–8 [Google Scholar]
  103. Xiong W, Knispel RA, Dietz HC. 103.  et al. 2008. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J. Vasc. Surg. 47:1166–72 [Google Scholar]
/content/journals/10.1146/annurev-med-100415-022956
Loading
Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models
Annual Review of Medicine 68, 51 (2017); https://doi.org/10.1146/annurev-med-100415-022956
/content/journals/10.1146/annurev-med-100415-022956
/content/journals/10.1146/annurev-med-100415-022956
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error